CompanyGraph
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
688505 · SSE · China
fd-zj.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.34B, above the global median of $1.15B
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.01BCNY1.34B · vs all stocks (USD)
Revenue (TTM)
654.94MCNY97.40M · vs all stocks (USD)
Profit Margin
-23.27%Beta
0.0860xvs all stocks
52-Week Change
-14.54%vs all stocks
Market Capitalization
9.01BCNY1.34B · vs all stocks (USD)
Enterprise Value
7.59BCNY1.13B · vs all stocks (USD)
Price to Sales (TTM)
14.09xPrice to Book (MRQ)
4.33xEnterprise to Revenue
11.58xEnterprise to EBITDA
-72.82xProfit Margin
-23.27%Return on Assets (TTM)
-4.01%Return on Equity (TTM)
-6.89%Revenue (TTM)
654.94MCNY97.40M · vs all stocks (USD)
Revenue per Share (TTM)
0.6320CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-17.20%Gross Profit (TTM)
587.88MCNY87.42M · vs all stocks (USD)
EBITDA (TTM)
-104.17MCNY-15.49M · vs all stocks (USD)
Net Income (TTM)
-152.39MCNY-22.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
189.40%Operating Cash Flow (TTM)
127.86MCNY19.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
139.28MCNY20.71M · vs all stocks (USD)
5-Year Average Dividend Yield
0.71%vs all stocks
Payout Ratio
234.79%Minority Interest (Equity)
425.61KCNYFY2025 · Dec 31, 2025Revenue
685.80MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
69.31MCNYFY2025 · Dec 31, 2025Gross Profit
616.49MCNYFY2025 · Dec 31, 2025Operating Income
-170.35MCNY-25.33M · vs all stocks (USD)
Pre-tax Income
-155.85MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.87MCNYFY2025 · Dec 31, 2025Net Income
-157.72MCNYFY2025 · Dec 31, 2025EBIT
-155.19MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-105.02MCNYFY2025 · Dec 31, 2025Research & Development
357.94MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
280.17MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.74MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.81MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
662.89KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-157.72MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
284.08KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
79.61MCNYFY2025 · Dec 31, 2025Free Cash Flow
48.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.15BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-157.72MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.54MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
213.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
17.53MCNYFY2025 · Dec 31, 2025Capital Expenditures
-31.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.29BCNYFY2025 · Dec 31, 2025Sale of Investments
3.30BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.21MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-31.10MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-31.10MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.04BSharesUpdated Aug 21, 2026Float Shares
426.83MSharesUpdated Aug 21, 2026% Held by Insiders
60.55%vs all stocks
% Held by Institutions
0.51%vs all stocks
Total Cash (MRQ)
1.13BCNY168.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.09CNYUpdated Aug 21, 2026Total Debt (MRQ)
13.27MCNY1.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0063xCurrent Ratio (MRQ)
7.46xBook Value per Share (MRQ)
2.04CNYUpdated Aug 21, 2026Total Assets
2.39BCNY355.51M · vs all stocks (USD)
Total Current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Liabilities
273.93MCNYFY2025 · Dec 31, 2025Total Non-current Assets
905.13MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
28.31MCNYFY2025 · Dec 31, 2025Total Current Liabilities
245.62MCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Accounts Receivable
201.34MCNYFY2025 · Dec 31, 2025Inventory
33.21MCNYFY2025 · Dec 31, 2025Accounts Payable
6.07MCNYFY2025 · Dec 31, 2025Short-term Debt
5.35MCNYFY2025 · Dec 31, 2025Long-term Debt
9.34MCNYFY2025 · Dec 31, 2025Common Stock (Book)
103.66MCNYFY2025 · Dec 31, 2025Retained Earnings
676.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.12BCNY314.78M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
6.58CNYUpdated Aug 21, 202652-Week High
10.55CNYUpdated Aug 21, 202652-Week Change
-14.54%vs all stocks
Beta
0.0860xvs all stocks
50-Day MA
7.54CNYUpdated Aug 21, 2026200-Day MA
8.06CNYUpdated Aug 21, 2026Avg 10-Day Volume
18.63MSharesUpdated Aug 21, 2026Avg 30-Day Volume
11.39MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.1300CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.34B, above the global median of $1.15BNotable
Market cap (USD): 1,340,103,139.2Global Median: 1,146,734,693.424
Levered free cash flow is $20.71M, above the global median of $16.24MNotable
Levered free cash flow (USD): 20,713,028.332Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
China Marine Information Systems Company Limited
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Wintao Communications Co.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease